Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171808 | 0.85 | RAB9A (0.51) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL31688404 | 0.83 | HDAC8 (0.57) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL203767 | 0.82 | TSHR (0.56) | RAB9ANPC1TSHRALDH1A1GRM5 | |
| SCHEMBL13527496 | 0.82 | NPC1 (0.49) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL8003959 | 0.81 | CSNK1D (0.50) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL14336396 | 0.81 | CSNK1D (0.54) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL8003960 | 0.81 | CSNK1D (0.50) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL26333756 | 0.81 | CSNK1D (0.50) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL2530328 | 0.81 | CSNK1D (0.47) | RAB9ANPC1TSHRCSNK1DADORA3 | |
| SCHEMBL14112017 | 0.80 | KMT2A (0.65) | RAB9ATSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4647783-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2002518388-A | — | — | 2002-06-25 | — | — | JP | claimed |
| US-6407255-B2 | THERAPY FOR PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2002-06-18 | — | — | US | claimed |
| EP-1087966-B1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME (GB) | 2002-05-08 | — | — | EP | claimed |
| US-20020019524-A1 | Chemical synthesis of morpholine derivatives | MERCK SHARP & DOHME LIMITED | 2002-02-14 | — | — | US | claimed |
| EP-1087966-A1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065900-A1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-23 | — | — | WO | claimed |
| US-6407255-B2 | THERAPY FOR PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2002-06-18 | — | — | US | disclosed |
| EP-1087966-B1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME (GB) | 2002-05-08 | — | — | EP | disclosed |
| US-20020019524-A1 | Chemical synthesis of morpholine derivatives | MERCK SHARP & DOHME LIMITED | 2002-02-14 | — | — | US | disclosed |
| US-6297376-B1 | POTENT AND SELECTIVE SUBSTANCE P (OR NEUROKININ-1) RECEPTOR ANTAGONISTS. ONE-STEP ALKYLATION WITH 3-CHLOROMETHYL-1,2,4-TRIAZOLIN-5-ONE, | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019524-A1 | Chemical synthesis of morpholine derivatives | OPRM1, OPRK1, OPRL1 | RAB9A 1917/4885NPC1 397/4885TSHR 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.